http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Keumhee Chough Carriere ) (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
( Jun Young Kim ),( Dong Hyun Sinn ),( Geum Youn Gwak ),( Gyu Seong Choi ),( Aldosri Meshal Saleh ),( Jae Won Joh ),( Sung Ki Cho ),( Sung Wook Shin ),( Keumhee Chough Carriere ),( Joong Hyun Ahn ),( 대한간학회 2016 Clinical and Molecular Hepatology(대한간학회지) Vol.22 No.2
Background/Aims: Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality. Methods: In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed. Results: The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decision-tree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1.B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by ‘oligo’ (2.4) nodules of intermediate size (5.10 cm) when the AFP levels was <400 ng/ml, or ‘oligo’ (2.4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3). Conclusions: SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates. (Clin Mol Hepatol 2016;22:250-258)
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
